Phase III trial for KLU156 (ganaplacide/lumefantrine, or GanLum), meets primary endpoint of non-inferiority to standard of care Coartem® (artemether-lumefantrine) Demonstrates PCR-corrected cure rate ...
Sports have a universal appeal that transcends boundaries. Each weekend, the NFL ignites millions of passionate fans from across the country, demonstrating the deep connection and power of community.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback